JP2022542450A5 - - Google Patents
Info
- Publication number
- JP2022542450A5 JP2022542450A5 JP2022506483A JP2022506483A JP2022542450A5 JP 2022542450 A5 JP2022542450 A5 JP 2022542450A5 JP 2022506483 A JP2022506483 A JP 2022506483A JP 2022506483 A JP2022506483 A JP 2022506483A JP 2022542450 A5 JP2022542450 A5 JP 2022542450A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- variable region
- chain variable
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025047199A JP2025102836A (ja) | 2019-08-02 | 2025-03-21 | 抗ｃｔｌａ４／抗ｐｄ－１二重特異性抗体及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910711122 | 2019-08-02 | ||
| CN201910711122.4 | 2019-08-02 | ||
| CN201911224135.5 | 2019-12-02 | ||
| CN201911224135 | 2019-12-02 | ||
| PCT/CN2020/106309 WO2021023117A1 (zh) | 2019-08-02 | 2020-07-31 | 抗ctla4-抗pd-1双特异性抗体及其用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025047199A Division JP2025102836A (ja) | 2019-08-02 | 2025-03-21 | 抗ｃｔｌａ４／抗ｐｄ－１二重特異性抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022542450A JP2022542450A (ja) | 2022-10-03 |
| JP2022542450A5 true JP2022542450A5 (enExample) | 2023-07-28 |
| JP7655896B2 JP7655896B2 (ja) | 2025-04-02 |
Family
ID=74483591
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506483A Active JP7655896B2 (ja) | 2019-08-02 | 2020-07-31 | 抗ｃｔｌａ４／抗ｐｄ－１二重特異性抗体及びその使用 |
| JP2025047199A Pending JP2025102836A (ja) | 2019-08-02 | 2025-03-21 | 抗ｃｔｌａ４／抗ｐｄ－１二重特異性抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025047199A Pending JP2025102836A (ja) | 2019-08-02 | 2025-03-21 | 抗ｃｔｌａ４／抗ｐｄ－１二重特異性抗体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220275089A1 (enExample) |
| EP (1) | EP4008730A4 (enExample) |
| JP (2) | JP7655896B2 (enExample) |
| KR (1) | KR20220053578A (enExample) |
| CN (1) | CN112300286A (enExample) |
| AU (1) | AU2020325350A1 (enExample) |
| BR (1) | BR112022002013A2 (enExample) |
| CA (1) | CA3146780A1 (enExample) |
| IL (2) | IL290255B2 (enExample) |
| MX (1) | MX2022001321A (enExample) |
| PH (1) | PH12022550243A1 (enExample) |
| WO (1) | WO2021023117A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| CN109053895B (zh) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| BR112022002028A2 (pt) * | 2019-08-02 | 2022-04-12 | Cttq Akeso Shanghai Biomed Tech Co Ltd | Anticorpo anti-pd-1 e uso farmacêutico do mesmo |
| US20230118596A1 (en) * | 2020-03-05 | 2023-04-20 | Merck Sharp & Dohme Llc | Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically accpetable salt thereof |
| EP4190819A4 (en) * | 2021-03-12 | 2024-08-14 | Akeso Biopharma, Inc. | PHARMACEUTICAL COMBINATION CONTAINING BISPECIFIC ANTI-PD-1-ANTI-VEGFA ANTIBODY, AND USE THEREOF |
| CN115073588B (zh) * | 2021-03-12 | 2024-06-18 | 中山康方生物医药有限公司 | 提高含有免疫球蛋白Fc片段的药物的安全性的方法 |
| CN115192718A (zh) * | 2021-04-14 | 2022-10-18 | 中山康方生物医药有限公司 | 抗cd47的单克隆抗体及其用途 |
| EP4324854A4 (en) * | 2021-04-14 | 2025-04-23 | Akeso Pharmaceuticals, Inc. | USE OF ANTIBODIES IN ANTITUMOR TREATMENT |
| IL310217A (en) * | 2021-07-23 | 2024-03-01 | Akeso Biopharma Inc | Pharmaceutical composition and use |
| WO2023160647A1 (zh) * | 2022-02-24 | 2023-08-31 | 康方药业有限公司 | 包含抗ctla4-抗pd-1双特异性抗体和西奥罗尼的药物组合 |
| CA3253514A1 (en) * | 2022-03-07 | 2023-09-14 | Medimmune Llc | TREATMENT METHODS USING CTLA-4 AND PD-1 BISPECIFIC ANTIBODIES |
| WO2023198089A1 (zh) * | 2022-04-13 | 2023-10-19 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| CN117679505A (zh) | 2022-09-09 | 2024-03-12 | 中山康方生物医药有限公司 | 药物组合及用途 |
| CA3208447A1 (en) * | 2022-09-09 | 2024-03-09 | Akeso Biopharma, Inc. | Therapeutic combination and use thereof |
| KR20250122541A (ko) | 2022-10-25 | 2025-08-13 | 사이즈믹 테라퓨틱, 인코포레이티드. | 변이체 IgG FC 폴리펩티드 및 그 용도 |
| WO2024141014A1 (zh) * | 2022-12-30 | 2024-07-04 | 康方药业有限公司 | Cd74的医药用途 |
| JP2026507907A (ja) * | 2023-03-07 | 2026-03-06 | アケソ・ファーマ・カンパニー，リミテッド | 抗ｃｔｌａ４抗ｐｄ－１二重特異性抗体を含有する医薬組成物とその使用 |
| CN121219403A (zh) * | 2023-03-31 | 2025-12-26 | 上海细胞治疗集团股份有限公司 | 双特异性抗体及自分泌双特异性抗体的工程化免疫细胞 |
| CN118767127A (zh) * | 2023-04-10 | 2024-10-15 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体的医药用途 |
| WO2025157267A1 (zh) * | 2024-01-25 | 2025-07-31 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双特异性抗体的医药用途 |
| WO2025201450A1 (zh) * | 2024-03-27 | 2025-10-02 | 康方汇科(上海)生物有限公司 | 药物组合及用途 |
| CN120919303A (zh) * | 2024-05-10 | 2025-11-11 | 康方汇科(上海)生物有限公司 | 药物组合及用途 |
| CN120965861B (zh) * | 2025-10-22 | 2026-02-13 | 杭州博茵生物技术有限公司 | 一种Fc效应消除的新型骨架流式抗体及其制备方法与应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU9598601A (en) | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| KR100804566B1 (ko) | 2003-12-25 | 2008-02-20 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 4-(3-클로로-4-(시클로프로필아미노카르보닐)아미노페녹시)-7-메톡시-6-퀴놀린카르복사미드의 염 또는 그 용매화물의 결정 및 이들의 제조 방법 |
| EP2471813B1 (en) * | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| US8148532B2 (en) | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
| AU2009288730B2 (en) * | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| US8961967B2 (en) * | 2009-11-30 | 2015-02-24 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| CA2785907A1 (en) * | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Ron binding constructs and methods of use thereof |
| JP6180663B2 (ja) * | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| KR20250057128A (ko) * | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| RU2693661C2 (ru) | 2016-03-04 | 2019-07-03 | Сычуань Келунь-Байотек Байофармасьютикал Ко., Лтд. | Антитело против pdl-1, его фармацевтическая композиция и применение |
| CN109862910A (zh) * | 2016-08-03 | 2019-06-07 | 小利兰·斯坦福大学托管委员会 | 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效 |
| WO2018035710A1 (en) * | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| CN106967172B (zh) * | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| CN106977602B (zh) * | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| AU2017371070B2 (en) * | 2016-12-09 | 2025-01-02 | Alector Llc | Anti-SIRP-alpha antibodies and methods of use thereof |
| CN106699891B (zh) * | 2017-01-25 | 2019-04-09 | 北京天广实生物技术股份有限公司 | 一种抗pd-l1抗体、其药物组合物及其用途 |
| EP3634485A4 (en) * | 2017-06-07 | 2021-07-21 | Silverback Therapeutics, Inc. | CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES |
| CN109762068A (zh) * | 2018-08-09 | 2019-05-17 | 源道隆（苏州）医学科技有限公司 | 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用 |
-
2020
- 2020-07-31 WO PCT/CN2020/106309 patent/WO2021023117A1/zh not_active Ceased
- 2020-07-31 MX MX2022001321A patent/MX2022001321A/es unknown
- 2020-07-31 AU AU2020325350A patent/AU2020325350A1/en active Pending
- 2020-07-31 JP JP2022506483A patent/JP7655896B2/ja active Active
- 2020-07-31 PH PH1/2022/550243A patent/PH12022550243A1/en unknown
- 2020-07-31 EP EP20850855.6A patent/EP4008730A4/en active Pending
- 2020-07-31 IL IL290255A patent/IL290255B2/en unknown
- 2020-07-31 BR BR112022002013A patent/BR112022002013A2/pt unknown
- 2020-07-31 KR KR1020227006972A patent/KR20220053578A/ko not_active Ceased
- 2020-07-31 IL IL321822A patent/IL321822A/en unknown
- 2020-07-31 US US17/630,467 patent/US20220275089A1/en active Pending
- 2020-07-31 CN CN202010757322.6A patent/CN112300286A/zh active Pending
- 2020-07-31 CA CA3146780A patent/CA3146780A1/en active Pending
-
2025
- 2025-03-21 JP JP2025047199A patent/JP2025102836A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022542450A5 (enExample) | ||
| US12331118B2 (en) | Humanized anti-human-PD-1 antibody and methods of using them for cancer treatment | |
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| JP2025102836A5 (enExample) | ||
| IL293241A (en) | Bispecific antibody, anti-1-pd, anti-vegfa, pharmaceutical preparation containing it and its use | |
| CA3058477A1 (en) | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same | |
| JP2023522730A5 (enExample) | ||
| JP2024509018A5 (enExample) | ||
| JP2024515396A5 (enExample) | ||
| EP4324854A1 (en) | Use of antibody in anti-tumor treatment | |
| WO2021222746A2 (en) | THERAPEUTIC SIRPα ANTIBODIES | |
| JP2025511002A (ja) | 活性化可能な二重特異性抗ｃｄ３および抗ｐｄ－ｌ１タンパク質ならびにその使用 | |
| EP4678186A1 (en) | Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and use thereof | |
| TH2201000670A (th) | แอนติบอดีชนิดไบสเปซิฟิกสารต้าน ctla4/สารต้าน pd-1 และการใช้ของสิ่งเหล่านั้น | |
| HK40121654A (zh) | 抗体在抗肿瘤治疗中的用途 | |
| HK40114665A (zh) | 包含抗ctla4-抗pd-1双特异性抗体的药物组合及其用途 | |
| HK40102352A (en) | Humanized anti-human-pd-1 antibody | |
| WO2025208010A1 (en) | Antibodies targeting human basal cell adhesion molecule | |
| CN118767127A (zh) | 抗ctla4-抗pd-1双特异性抗体的医药用途 | |
| HK40101066A (en) | Use of antibody in anti-tumor treatment | |
| KR20220143904A (ko) | 사람 4-1bb 항진제 항체 및 이의 사용 방법 | |
| HK40060816A (en) | Humanized anti-human-pd-1 antibody | |
| HK40060816B (en) | Humanized anti-human-pd-1 antibody |